PsAPASH: A new syndrome associated with hidradenitis suppurativa with response to tumor necrosis factor inhibition  by Saraceno, Rosita et al.
Fig 1. Generalized prurigo nodularis. Patient 1 before (A) and after (B) a course of modified
Goeckerman therapy.
J AM ACAD DERMATOL
JANUARY 2015
e42 LettersPfizer, and Merck. Dr Berger is a consultant for
Hyperion Therapeutics and Prescription Solu-
tions. Mr Sorenson and Dr Levin have no
conflicts of interest to declare.
Correspondence to: Eric Sorenson, AB, 515 Spruce
Street, San Francisco, CA 94118
E-mail: esorenso@usc.edu
REFERENCES
1. AkiyamaT, CarstensMI, Carstens E. Enhanced scratchingevoked
by PAR-2 agonist and 5-HT but not histamine in a mousemodel
of chronic dry skin itch. Pain 2010;151(2):378-83.
2. Rukwied RR, Main M, Weinkauf B, et al. NGF sensitizes
nociceptors for cowhage- but not histamine-induced itch in
human skin. J Invest Dermatol 2013;133(1):268-70.
3. Steinhoff M, Neisius U, Ikoma A, et al. Proteinase-activated
receptor-2 mediates itch: a novel pathway for pruritus in
human skin. J Neurosci 2003;23(15):6176-80.
4. Sonkoly E, Muller A, Lauerma AI, et al. IL-31: a new link
between T cells and pruritus in atopic skin inflammation.
J Allergy Clin Immunol 2006;117(2):411-7.
5. Johansson O, Liang Y, Emtestam L. Increased nerve growth
factor- and tyrosine kinase A-like immunoreactivities in
prurigo nodularis skin e an exploration of the cause of
neurohyperplasia. Arch Dermatol Res 2002;293(12):614-9.
6. Liang Y, Jacobi HH, Reimert CM, et al. CGRP-immunoreactive
nerves in prurigo nodularisean exploration of neurogenic
inflammation. J Cutan Pathol 2000;27(7):359-66.
7. Wallengren J, Sundler F. Phototherapy reduces the number of
epidermal and CGRP-positive dermal nerve fibres. Acta Derm
Venereol 2004;84(2):111-5.
8. Tartar D, Bhutani T, Huynh M, et al. Update on the immuno-
logical mechanism of action behind phototherapy. J Drugs
Dermatol 2014;13(5):564-8.
http://dx.doi.org/10.1016/j.jaad.2014.09.050Open access under CC BY-NC-ND license.PsAPASH: A new syndrome associated with
hidradenitis suppurativa with response to
tumor necrosis factor inhibition
To the Editor: A 50-year-old man with refractory and
multitherapy-resistant hidradenitis suppurativa was
referred for evaluation after having been unsuccess-
fully treated with dapsone, oral isotretinoin, and
several cycles of antibiotics (clindamycin-rifampin,
tetracycline, cephalosporin) (Fig 1, A). He had
hidradenitis suppurativa since the age of 43 years,
wasoverweight andaheavy tobacco smoker, andhad
a medical history of acne, diabetes mellitus type 2,
arterial hypertension, hypertriglyceridemia, hiatal
hernia, depression, and psoriatic arthritis (PsA).
Active acne pustules and comedonal lesions were
observed on the face and neck; painful sterile
abscesses and hypertrophic scars were present at
the axillae and were classified as hidradenitis suppu-
rativa Hurley II stage of severity. The patient had also
erythematous scaly lesions on the scalp associated
with severe joint and diffuse inflammation leading to
the clinical diagnosis of PsA (Psoriasis Area Severity
Index score 1.2; DAS28-CRP4 5.78; pain visual analog
scale score 70). Two ulcerative lesions on his right leg
had a dusky erythematous undermined edge (Fig 1,
B), andwere clinically andhistologically diagnosed as
pyoderma gangrenosum after the exclusion of di-
agnoses including neutrophilic disorders, vasculopa-
thies, and infections. His quality of life was severely
hampered by disability and social discomfort.
Adalimumab is a highly specific tumor necrosis
factor (TNF)-alfa inhibitor, binding to both soluble
Fig 1. Clinical details of PsAPASH syndrome. Hidradenitis suppurativa: scarring and multiple
interconnected painful lesions localized at the axillae (Hurley stage II) (A). Ulcerative lesions
localized at the lower extremities clinically and histologically diagnosed as pyoderma
gangrenosum (B).
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proinflammatory cytokine with a pathogenetic role
in several immune-mediated diseases such as
psoriasis, hidradenitis suppurativa, and pyoderma
gangrenosum. The efficacy and safety of adalimu-
mab in treating PsA is largely demonstrated, whereas
limited evidence of its off-label use in treating
hidradenitis suppurativa, pyoderma gangrenosum,
or concomitant skin disorders has been
reported.1-3 Randomized, double-blind, placebo-
controlled studies have assessed the efficacy and
safety of adalimumab therapy in patients affected by
hidradenitis suppurativa.1,2
Adalimumab therapy was initiated at a dose of 40
mg every other week. A marked and rapid improve-
ment in PsA and psoriatic skin lesions (Psoriasis Area
Severity Index score 0; DAS28-CRP4 1.21; pain visual
analog scale score 0) with concomitant clinical
remission of hidradenitis suppurativa and pyoderma
gangrenosum was observed after 4 weeks of treat-
ment. The effect was durable over the 36 weeks of
treatment, and adalimumab was well tolerated.
Hidradenitis suppurativa is notoriously difficult
to treat. Currently available therapeutic options
including antibiotics (clindamycin-rifampin-tetra-
cycline), isotretinoin, and dapsone. If antibiotics
are ineffective, excisional surgery remains a valid
therapeutic approach. In our case, hidradenitis
suppurativa associated with PsA, acne, andpyoderma gangrenosum was successfully treated
with adalimumab. Adalimumab was administered
at the recommended dose for PsA therapy, leading
to the resolution of the clinical symptoms of
psoriasis and complete remission of hidradenitis
suppurativa and pyoderma gangrenosum. Similar
to the spectrum of recently described autoinflam-
matory syndromes, namely PASH ( pyoderma gan-
grenosum, acne, and hidradenitis suppurativa),
PAPA ( pyogenic arthritis, acne, and pyoderma
gangrenosum), and PAPASH ( pyogenic arthritis,
pyoderma gangrenosum, acne, and hidradenitis
suppurativa), the concomitant diagnosis of PsA,
pyoderma gangrenosum, acne, and hidradenitis
suppurativa may represent a new syndrome; the
acronym could be PsAPASH.4,5 As shown in this
case, TNF-alfa inhibition may represent a prom-
ising therapeutic strategy for treating multiple
concomitant skin disorders, such as that with
common pathogenic mechanisms. However,
further clinical observations will be helpful to
establish the prevalence of this clinical entity
and its treatment.
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Fig 1. Total mastectomy of the right breast revealed Paget
disease with underlying foci of ductal carcinoma in situ
(shown above). (Hematoxylin-eosin stain; original magni-
fication: 3100.)
Fig 2. In the axilla, atypical large cells with prominent
nuclei and pale cytoplasm are present diffusely within the
epidermis. (Hematoxylin-eosin stain; original magnifica-
tion: 3200.)
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Synchronous Paget disease of the breast and
axilla
To the Editor: Mammary Paget disease (MPD) and
extramammary Paget disease (EMPD) are rare
acquired skin disorders having clinical features that
are similar to those of inflammatory or infectious skin
disorders. MPD is mostly associated with high-grade
ductal carcinoma in situ, whereas EMPD arises in
areas rich in apocrine glands. EMPD is classified into
primary and secondary EMPD; the latter is associated
with underlying malignancy and may arise as a result
of epidermal invasion of malignant adenocarcinoma
cells.
We report a rare case of synchronous Paget
disease. A 63-year-old woman presented concom-
itantly with crusting and erosion of the right nipple,
with brown plaques on the left axilla. Breast lesion
biopsy specimen indicated underlying foci of ductal
carcinoma in situ, which required total mastectomy
and sentinel lymph node biopsy. Axilla biopsy
specimen indicated EMPD, which required simpleresection of the left axilla lesion. Both tumors were
located in the epithelium (Figs 1 and 2), and axillary
sentinel lymph node biopsy specimen yielded
negative results. Because the operative margins
were negative and both tumors were staged as
TisN0M0, the treatment was deemed adequate.
Gross cystic disease fluid protein-15 and estrogen
receptor were expressed in the breast, but not in the
axilla tumor cells. Immunohistochemical and path-
ological analyses indicated that neither of these
were secondary metastatic lesions, but suggested
that they arose from independent tumorigenic
events.
Cases of synchronous MPD and EMPD are
extremely rare; to our knowledge, only 2 other cases
have been reported. This report is the first to
our knowledge that describes the simultaneous
diagnosis of synchronous Paget disease of the breast
and axilla.
